Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LYVISPAH

BACLOFEN

Standard Dose
5MG/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LYVISPAH is listed in Drugs@FDA under application 215422 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BACLOFEN Form and strength GRANULES;ORAL - 5MG/PACKET Sponsor STRIDES PHARMA INTL Submission history Latest submission status date: 2021-11-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview LYVISPAH is listed in Drugs@FDA under application 215422 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BACLOFEN Form and strength GRANULES;ORAL - 5MG/PACKET Sponsor STRIDES PHARMA INTL Submission history Latest submission status date: 2021-11-22 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.